Trials Sponsors Conditions Drugs Pricing

Conditions

Interstitial Lung Diseases (ILD)

Keywords

treatable traitsinterstitial lung diseasepulmonary fibrosismultidisciplinary

Outcome Measures

Primary Outcomes (1)

Health-related quality of life
Kings brief interstitial lung disease score that has been validated in quality of life for ILD patients.
from enrolment to 6 months post intervention.

Secondary Outcomes (2)

Progression free survival
from enrolment to 12 months post intervention (14 months post enrolment)
Exercise capacity
from enrolment to 12 months post intervention (14 months post enrolment)

Other Outcomes (1)

Economic evaluation
from enrolment to 12 months post intervention (14 months post enrolment)

Study Arms (2)

Treatable Traits model of care

EXPERIMENTAL

Embedded multidisciplinary clinic. This involves multidimensional assessment of patients with MDT review to determine presence of treatable traits and their specific management.

Other: Treatable traits model of care

Standard of Care

NO INTERVENTION

Standard of care where physician-led ILD clinic. All referrals and comorbidity management as guided by physician.

Interventions

Treatable traits model of careOther

Embedded multidisciplinary clinic with treatable traits model of care.

Treatable Traits model of care

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Included participants will be aged ≥ 18 years with a physician-confirmed diagnosis of fibrotic ILD. Fibrotic ILD is defined as presence of fibrotic changes on CT in the opinion of the investigator. All ILD subtypes, excluding sarcoidosis, will be included. Participants will need to be able to provide consent to participate and be established on stable ILD treatment for 1 month prior to study initiation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Sir Charles Gairdner Hospital
Othercollaborator
Fiona Stanley Hospital
Othercollaborator
The University of Western Australia

Study Sites (2)

Sir Charles Gairdner Hospital

Perth, Western Australia, 6009, Australia

NOT_YET_RECRUITING

Megan Harrison, MBBS FRACPCONTACT+6147504307 he18696@health.wa.gov.au

Lisa Bateman, BSNCONTACT+61478 279 934 scgh.ild@health.wa.gov.au

Megan Harrison, MBBS FRACPPRINCIPAL INVESTIGATOR

Vidya Navaratnam, FRACP, MD, PHDSUB INVESTIGATOR

Fiona Stanley Hospital

MeSH Terms

Conditions

Lung Diseases, InterstitialPulmonary Fibrosis

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Yuben Moodley, MBSS, FRACP, MD, PHD
The University of Western Australia
PRINCIPAL INVESTIGATOR

Central Study Contacts

Megan Harrison, MBSS (Hons) FRACP

CONTACT

+61 08 6457 3333 megan.harrison@health.wa.gov.au

Yuben Moodley, MBSS, FRACP, MD, PHD

CONTACT

61086152 2222

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Dr.

Study Record Dates

First Submitted

October 1, 2024

First Posted

October 3, 2024

Study Start

September 3, 2025

Actual (reported)

Primary Completion

December 2026

Estimated

Treatable Traits in Interstitial Lung Disease

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Other Outcomes (1)

Study Arms (2)

Treatable Traits model of care

Standard of Care

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Other Outcomes (1)

Study Arms (2)

Treatable Traits model of care

Standard of Care

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

Locations